


L1 HAS NO ANSWERS
L1 STR



VAR G1=O/S/N/C
REP G2=(0-3) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 7 3
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> d his 13

(FILE 'REGISTRY' ENTERED AT 09:02:20 ON 12 NOV 2008)
L3 112 S L1 FUL

=> d his 14

(FILE 'CAPLUS' ENTERED AT 09:07:27 ON 12 NOV 2008)
L4 36 S L3

=> d his 16

(FILE 'CAPLUS' ENTERED AT 09:07:27 ON 12 NOV 2008)
L6 5 S L4 AND PY<=2002

=> d bib 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:794958 CAPLUS
DN 135:331296
TI Preparation of stereospecific synthetic tubulysins and intermediates
IN Hofle, Gerhard; Leibold, Thomas; Steinmetz, Heinrich
PA Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf), Germany
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10008089	A1	20011031	DE 2000-10008089	20000222 <--
PRAI	DE 2000-10008089		20000222		
OS	CASREACT 135:331296; MARPAT 135:331296				

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2000:702489 CAPLUS
 DN 134:15006
 TI Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties
 AU Sasse, Florenz; Steinmetz, Heinrich; Heil, Jurgen; Hofle, Gerhard; Reichenbach, Hans
 CS GBF, Gesellschaft fur Biotechnologische Forschung mbH, Abteilung Naturstoffbiologie, Braunschweig, D-38124, Germany
 SO Journal of Antibiotics (2000), 53(9), 879-885
 CODEN: JANTAJ; ISSN: 0021-8820
 PB Japan Antibiotics Research Association
 DT Journal
 LA English
 RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:208578 CAPLUS
 DN 128:256473
 OREF 128:50787a,50790a
 TI Antimycotic and cytostatic compounds manufacture with Archangium
 IN Reichenbach, Hans; Hoefle, Gerhard; Sasse, Florenz; Steinmetz, Heinrich
 PA Gesellschaft fuer Biotechnologische Forschung m.b.H. (GBF), Germany
 SO Ger. Offen., 16 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19638870	A1	19980326	DE 1996-19638870	19960923 <--
	WO 9813375	A1	19980402	WO 1997-EP5095	19970917 <--
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9745550	A	19980417	AU 1997-45550	19970917 <--
PRAI	DE 1996-19638870	A	19960923		
	WO 1997-EP5095	W	19970917		

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1993:22591 CAPLUS
 DN 118:22591
 OREF 118:4261a,4264a
 TI Design and synthesis of novel FKBP inhibitors
 AU Hauske, James R.; Dorff, Peter; Julin, Susan; DiBrino, Joseph; Spencer, Robin; Williams, Rebecca
 CS Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA
 SO Journal of Medicinal Chemistry (1992), 35(23), 4284-96
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1990:591965 CAPLUS
 DN 113:191965

OREF 113:32513a,32516a

TI Preparation of N-[1-(3-lysylamino-2-carboxylpropyl)-1-cyclopentanecarbonyl]tyrosine and analogs as cardiovascular agents

IN Danilewicz, John Christopher; James, Keith; Kobylecki, Ryszard Jurek

PA Pfizer Ltd., UK; Pfizer Inc.

SO Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 358398	A1	19900314	EP 1989-308740	19890830 <--
	EP 358398	B1	19930310		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4975444	A	19901204	US 1989-398675	19890825 <--
	IL 91460	A	19950831	IL 1989-91460	19890829 <--
	AT 86606	T	19930315	AT 1989-308740	19890830 <--
	ES 2054009	T3	19940801	ES 1989-308740	19890830 <--
	CA 1341046	C	20000704	CA 1989-610165	19890901 <--
	DK 8904362	A	19900306	DK 1989-4362	19890904 <--
	DK 175082	B1	20040524		
	FI 8904158	A	19900306	FI 1989-4158	19890904 <--
	FI 111715	B1	20030915		
	NO 8903546	A	19900306	NO 1989-3546	19890904 <--
	NO 177747	B	19950807		
	NO 177747	C	19951115		
	AU 8941052	A	19900308	AU 1989-41052	19890904 <--
	AU 604195	B2	19901206		
	HU 51293	A2	19900428	HU 1989-4562	19890904 <--
	HU 215440	B	20000428		
	DD 284222	A5	19901107	DD 1989-332345	19890904 <--
	ZA 8906760	A	19910424	ZA 1989-6760	19890904 <--
	PL 161527	B1	19930730	PL 1989-281295	19890904 <--
	RU 2012556	C1	19940515	RU 1989-4614874	19890904 <--
	CZ 282142	B6	19970514	CZ 1989-5108	19890904 <--
	CN 1040986	A	19900404	CN 1989-106909	19890905 <--
	CN 1031051	C	19960221		
	JP 02124862	A	19900514	JP 1989-230253	19890905 <--
	JP 06060144	B	19940810		
	RU 2108322	C1	19980410	RU 1993-4970	19930524 <--
PRAI	GB 1988-20844	A	19880905		
	EP 1989-308740	A	19890830		
OS	MARPAT 113:191965				

AN 1990:591965 CAPLUS

DN 113:191965

OREF 113:32513a,32516a

TI Preparation of N-[1-(3-lysylamino-2-carboxylpropyl)-1-cyclopentanecarbonyl]tyrosine and analogs as cardiovascular agents

IN Danilewicz, John Christopher; James, Keith; Kobylecki, Ryszard Jurek

PA Pfizer Ltd., UK; Pfizer Inc.

SO Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 358398	A1	19900314	EP 1989-308740	19890830 <--
	EP 358398	B1	19930310		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4975444	A	19901204	US 1989-398675	19890825 <--
	IL 91460	A	19950831	IL 1989-91460	19890829 <--
	AT 86606	T	19930315	AT 1989-308740	19890830 <--
	ES 2054009	T3	19940801	ES 1989-308740	19890830 <--
	CA 1341046	C	20000704	CA 1989-610165	19890901 <--
	DK 8904362	A	19900306	DK 1989-4362	19890904 <--
	DK 175082	B1	20040524		
	FI 8904158	A	19900306	FI 1989-4158	19890904 <--
	FI 111715	B1	20030915		
	NO 8903546	A	19900306	NO 1989-3546	19890904 <--
	NO 177747	B	19950807		
	NO 177747	C	19951115		
	AU 8941052	A	19900308	AU 1989-41052	19890904 <--
	AU 604195	B2	19901206		
	HU 51293	A2	19900428	HU 1989-4562	19890904 <--
	HU 215440	B	20000428		
	DD 284222	A5	19901107	DD 1989-332345	19890904 <--
	ZA 8906760	A	19910424	ZA 1989-6760	19890904 <--
	PL 161527	B1	19930730	PL 1989-281295	19890904 <--
	RU 2012556	C1	19940515	RU 1989-4614874	19890904 <--
	CZ 282142	B6	19970514	CZ 1989-5108	19890904 <--
	CN 1040986	A	19900404	CN 1989-106909	19890905 <--
	CN 1031051	C	19960221		
	JP 02124862	A	19900514	JP 1989-230253	19890905 <--
	JP 06060144	B	19940810		
	RU 2108322	C1	19980410	RU 1993-4970	19930524 <--
PRAI	GB 1988-20844	A	19880905		
	EP 1989-308740	A	19890830		

OS MARPAT 113:191965

IT 129981-38-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as cardiovascular agent)

RN 129981-38-0 CAPLUS

CN β -Alanine, L-2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]cyclopentyl]methyl]-N-[N2-(2-pyridinylcarbonyl)-L-lysyl]-, (S)- (9CI) (CA INDEX NAME)

